Annovis Bio to Host Webinar on Alzheimer's and Parkinson's Drug Progress

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company focused on neurodegenerative diseases, has announced it will host a corporate update webinar on September 2, 2026, at 4 p.m. EDT. The webinar, led by founder, President and CEO Maria Maccecchini, Ph.D., will cover recent progress, ongoing clinical programs, and upcoming milestones, including the fully enrolled pivotal Phase 3 Alzheimer's disease (AD) trial. Top-line data and regulatory submissions are expected in 2027.

Annovis is developing buntanetap, an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP-43. By targeting these proteins, the drug aims to address the underlying causes of neurodegeneration and potentially halt disease progression, improving cognitive and motor functions in patients with AD and Parkinson's disease (PD).

The company also plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data. Meanwhile, its PD open-label study is already underway, and discussions are ongoing regarding the initiation of a Parkinson's disease dementia program. These efforts underscore Annovis's commitment to advancing treatments for these debilitating conditions.

The webinar will include a live question-and-answer session, providing investors and stakeholders an opportunity to engage directly with management. This announcement comes as Annovis continues to make strides in its clinical development pipeline, with the AD trial fully enrolled and data readouts anticipated in the near term.

For more information about the webinar and Annovis Bio, visit this press release. Additional details about the company and its programs can be found at Annovis Bio's website. The company also maintains a newsroom at IBN's newsroom for the latest updates.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to developing treatments for Alzheimer's and Parkinson's diseases. The company's lead drug candidate, buntanetap, is an investigational therapy that works through a specific RNA-targeting mechanism, offering a novel approach to combating neurodegeneration. With the upcoming webinar and continued clinical progress, Annovis is positioning itself as a key player in the fight against these devastating diseases.